Thermo Fisher Surges on Strong Q2 Results | Business and Finance News

Thermo Fisher smashed Q2 expectations with $11.99 billion in sales—up 10% year-over-year—and stronger-than-anticipated earnings, proving their growth is broad-based across pharma, biotech, industrial, and diagnostics. New high-end gear and AI-driven software are fueling market share gains, while recent acquisitions are already delivering revenue and operational wins. Leadership is laser-focused on high-potential areas, and ahead, they’re betting on continued momentum in pharma and biotech, plus a clinical research rebound—while spinning off their microbiology unit to free up cash for R&D and stock buybacks. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cc6fb966b5119077